These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38904202)

  • 1. Public neoantigens in breast cancer immunotherapy (Review).
    Sueangoen N; Thuwajit P; Yenchitsomanus PT; Thuwajit C
    Int J Mol Med; 2024 Jul; 54(1):. PubMed ID: 38904202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer.
    Benvenuto M; Focaccetti C; Izzi V; Masuelli L; Modesti A; Bei R
    Semin Cancer Biol; 2021 Jul; 72():65-75. PubMed ID: 31698088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
    Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
    Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors.
    Shi Y; Jing B; Xi R
    Genome Biol; 2023 Jul; 24(1):169. PubMed ID: 37461029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Neoantigens Can Induce CD8
    Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
    Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
    Wang Y; Shi T; Song X; Liu B; Wei J
    Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
    Zhao W; Wu J; Chen S; Zhou Z
    Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
    Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
    Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
    Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
    Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy targeting neoantigens.
    Lu YC; Robbins PF
    Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
    Zhou S; Liu S; Zhao L; Sun HX
    Front Oncol; 2022; 12():786438. PubMed ID: 35387130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting public neoantigens for cancer immunotherapy.
    Pearlman AH; Hwang MS; Konig MF; Hsiue EH; Douglass J; DiNapoli SR; Mog BJ; Bettegowda C; Pardoll DM; Gabelli SB; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S
    Nat Cancer; 2021 May; 2(5):487-497. PubMed ID: 34676374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoantigen identification: Technological advances and challenges.
    Pu T; Peddle A; Zhu J; Tejpar S; Verbandt S
    Methods Cell Biol; 2024; 183():265-302. PubMed ID: 38548414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
    Kiyotani K; Chan HT; Nakamura Y
    Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.